Bottom line
What is EMLAX's expense ratio?
EMLAX's expense ratio is 1.11%, or about $111 a year on every $10,000 invested. That is more expensive than 66% of emerging-markets bond funds we track (median 0.92%). This share class also charges a front-end sales load of up to 4.25%, taken from your investment when you buy. Its expense ratio includes a 0.25% 12b-1 marketing fee.
Updated Feb 26, 2026
EMLAX fee table
| Net expense ratio | 1.11% |
|---|---|
| Gross expense ratio | 1.25% |
| Management fee | 0.75% |
| 12b-1 (distribution) fee | 0.25% |
| Other expenses | 0.25% |
| Fee waiver / reimbursement | -0.14% |
| Max front-end sales load | 4.25% |
| Max deferred sales charge | 1% |
Source: Fund prospectus fee table, filed Feb 26, 2026
What EMLAX costs in dollars
The SEC requires every fund to show what a $10,000 investment would cost, assuming 5% annual returns and that you sell at the end of each period:
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| EMLAX | $533 | $791 | $1,069 | $1,860 |
Source: Fund prospectus expense example
The long-run cost of fees
On $100,000 growing at 6% a year for 20 years, a 1.11% expense ratio costs roughly $60,900 in lost growth, versus about $51,300 for the median emerging-markets bond fund (0.92%).